(2R,4S,5S)-2-[(3S,5S,6S)-6-[(3S,5S,6S)-6-[(3S,5S,6S)-6-[(3S,5S,6R)-6-[(3S,5S,6R)-6-[(3S,4R)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-2-ethyl-4,5-dihydroxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-ethyloxane-3,4,5-triol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,4S,5S)-2-[(3S,5S,6S)-6-[(3S,5S,6S)-6-[(3S,5S,6S)-6-[(3S,5S,6R)-6-[(3S,5S,6R)-6-[(3S,4R)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-2-ethyl-4,5-dihydroxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-ethyloxane-3,4,5-triol
• 化学式: C₄₄H₇₆O₃₃
• 分子量: 1133.1
• InChiKey: JHJFOGZVVYQMEY-WNMRJQIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -12.3
• 重原子数：
  77
• 可旋转键数：
  19
• 环数：
  7.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  525
• 氢给体数：
  20
• 氢受体数：
  33

文献信息

• TREATMENT OF CANCER
  申请人：CERULEAN PHARMA INC.

  公开号：US20140105891A1

  公开（公告）日：2014-04-17

  Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

  提供了与包含CDP-拓扑异构酶抑制剂的组合物相关的方法，例如包括CDP-喜树碱或喜树碱衍生物结合物的组合物，例如CRLX101。
• US20140255374A1
  申请人：——

  公开号：US20140255374A1

  公开（公告）日：2014-09-11